Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.

View in: PubMed

subject areas

Antigens, CD19
Biological Products
Humans
Lymphoma, Large B-Cell, Diffuse
Middle Aged
Receptors, Antigen, T-Cell
Retrospective Studies
United States

authors with profiles

Peter Riedell